Therapeutic drug monitoring of intravenous anti-tuberculous therapy: management of an 8-month-old child with tuberculous meningitis

References

• Thwaites G, Chau TT, Mai NT, et al. Tuberculous meningitis. J Neurol Neurosurg Psychiatr. 2000;68:289–299.
   Google Scholar
• Muzumdar D, Vedantam R, Chandrashekhar D. Tuberculosis of the central nervous system in children. Childs Nerv Syst. 2018;34:1925–1935.
   Google Scholar
• Karande S, Gupta V, Kulkarni M, et al. Prognostic clinical variables in childhood tuberculous meningitis: an experience from Mumbai, India. Neurol India. 2005;53:191–195; discussion 195–196.
   Google Scholar
• van Well GTJ, Paes BF, Terwee CB, et al. Twenty years of pediatric tuberculous meningitis: a retrospective cohort study in the western cape of South Africa. Pediatrics. 2009;123:e1–e8.
   Google Scholar
• van Toorn R, Schaaf HS, Laubscher JA, et al. Short intensified treatment in children with drug-susceptible tuberculous meningitis. Pediatr Infect Dis J. 2014;33:248–252.
   Google Scholar
• World Health Organization. Guidance for national tuberculosis programmes on the management of tuberculosis in children. Geneva: WHO; 2015.
   Google Scholar
• Thee S, Seddon JA, Donald PR, et al. Pharmacokinetics of isoniazid, rifampin, and pyrazinamide in children younger than two years of age with tuberculosis: evidence for implementation of revised World Health Organization recommendations. Antimicrob Agents Chemother. 2011;55:5560–5567.
   Google Scholar
• Zvada SP, Denti P, Donald PR, et al. Population pharmacokinetics of rifampicin, pyrazinamide and isoniazid in children with tuberculosis: in silico evaluation of currently recommended doses. J Antimicrob Chemother. 2014;69:1339–1349.
   Google Scholar
• Chiang SS, Khan FA, Milstein MB, et al. Treatment outcomes of childhood tuberculous meningitis: a systematic review and meta-analysis. Lancet Infect Dis. 2014;14:947–957.
   Google Scholar
• Donald PR. Cerebrospinal fluid concentrations of antituberculosis agents in adults and children. Tuberculosis. 2010;90:279–292.
   Google Scholar
• Bekker A, Schaaf HS, Draper HR, et al. Pharmacokinetics of rifampin, isoniazid, pyrazinamide, and ethambutol in infants dosed according to revised WHO-recommended treatment guidelines. Antimicrob Agents Chemother. 2016;60:2171–2179.
   Google Scholar
• Mukherjee A, Lodha R, Kabra SK. Pharmacokinetics of first-line anti-tubercular drugs. Indian J Pediatr. 2019;86:468–478.
   Google Scholar
• Lu H, Rosenbaum S. Developmental pharmacokinetics in pediatric populations. J Pediatr Pharmacol Ther. 2014;19:262–276.
   Google Scholar
• Kearns GL, Abdel-Rahman SM, Alander SW, et al. Developmental pharmacology – drug disposition, action, and therapy in infants and children. N Engl J Med. 2003;349:1157–1167.
   Google Scholar
• Schaaf HS, Parkin DP, Seifart HI, et al. Isoniazid pharmacokinetics in children treated for respiratory tuberculosis. Arch Dis Child. 2005;90:614–618.
   Google Scholar
• Thee S, Detjen A, Quarcoo D, et al. Ethambutol in paediatric tuberculosis: aspects of ethambutol serum concentration, efficacy and toxicity in children. Int J Tuberc Lung Dis. 2007;11:965–971.
   Google Scholar
• Thee S, Detjen AA, Wahn U, et al. Isoniazid pharmacokinetic studies of the 1960s: considering a higher isoniazid dose in childhood tuberculosis. Scand J Infect Dis. 2010;42:294–298.
   Google Scholar
• Pouplin T, Bang ND, Toi PV, et al. Naïve-pooled pharmacokinetic analysis of pyrazinamide, isoniazid and rifampicin in plasma and cerebrospinal fluid of Vietnamese children with tuberculous meningitis. BMC Infect Dis. 2016;16:144.
   Google Scholar
• Timmins GS, Deretic V. Mechanisms of action of isoniazid. Mol Microbiol. 2006;62:1220–1227.
   Google Scholar
• Mitchison DA. Role of individual drugs in the chemotherapy of tuberculosis. Int J Tuberc Lung Dis. 2000;4:796–806.
   Google Scholar
• Alsultan A, Peloquin CA. Therapeutic drug monitoring in the treatment of tuberculosis: an update. Drugs. 2014;74:839–854.
   Google Scholar
• Mukherjee A, Velpandian T, Singla M, et al. Pharmacokinetics of isoniazid, rifampicin, pyrazinamide and ethambutol in Indian children. BMC Infect Dis. 2015;15:126.
   Google Scholar
• Frydenberg AR, Graham SM. Toxicity of first-line drugs for treatment of tuberculosis in children: review. Trop Med Int Health. 2009;14:1329–1337.
   Google Scholar
• Donald PR, Gent WL, Seifart HI, et al. Cerebrospinal fluid isoniazid concentrations in children with tuberculous meningitis: the influence of dosage and acetylation status. Pediatrics. 1992;89:247–250.
   Google Scholar
• Schaaf H, Garcia-Prats A, Donald P. Antituberculosis drugs in children. Clin Pharmacol Ther. 2015;98:252–265.
   Google Scholar
• Savic RM, Ruslami R, Hibma JE, et al. Pediatric tuberculous meningitis: model-based approach to determining optimal doses of the anti-tuberculosis drugs rifampin and levofloxacin for children. Clin Pharmacol Ther. 2015;98:622–629.
   Google Scholar
• Yang H, Enimil A, Gillani FS, et al. Evaluation of the adequacy of the 2010 revised world health organization recommended dosages of the first-line antituberculosis drugs for children. Pediatr Infect Dis J. 2018;37:43–51.
   Google Scholar
• Hiruy H, Rogers Z, Mbowane C, et al. Subtherapeutic concentrations of first-line anti-TB drugs in South African children treated according to current guidelines: the PHATISA study. J Antimicrob Chemother. 2015;70:1115–1123.
   Google Scholar
• Ruslami R, Ganiem AR, Dian S, et al. Intensified regimen containing rifampicin and moxifloxacin for tuberculous meningitis: an open-label, randomised controlled phase 2 trial. Lancet Infect Dis. 2013;13:27–35.
   Google Scholar
• Peloquin CA. Therapeutic drug monitoring in the treatment of tuberculosis. drugs. 2002;62:2169–2183.
   Google Scholar
• Ramachandran G, Kumar AKH, Swaminathan S. Pharmacokinetics of anti-tuberculosis drugs in children. Indian J Pediatr. 2011;78:435–442.
   Google Scholar